Debiopharm International SA
- Country
- 🇨🇭Switzerland
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://debiopharm.com
Clinical Trials
71
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (70 trials with phase data)• Click on a phase to view related trials
A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults
- Conditions
- Healthy Participants
- Interventions
- Drug: Debio 1453PDrug: Placebo
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 88
- Registration Number
- NCT07035769
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Debio 1562M
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 134
- Registration Number
- NCT06969430
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 119
- Registration Number
- NCT06930625
- Locations
- 🇺🇸
Washington University-School of Medicine, Saint Louis, Missouri, United States
🇺🇸Palm Research Center Inc, Las Vegas, Nevada, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 66
- Registration Number
- NCT06395753
- Locations
- 🇺🇸
Bakersfield Institute of Advanced Urology, Bakersfield, California, United States
🇺🇸Valley Urology, Fresno, California, United States
🇺🇸Advanced Urology, Los Angeles, California, United States
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 56
- Registration Number
- NCT06129539
- Locations
- 🇺🇸
TMC HealthCare, Tucson, Arizona, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next